In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
The new aryl fluoroquinolones, Abbott 56619 and Abbott 56620, were compared to ciprofloxacin, norfloxacin and newer beta-lactam agents in standardized microtiter testing versus multidrug-resistant gram-negative bacilli. Ciprofloxacin, followed by Abbott 56620, was generally the most active quinolone and imipenem the most active beta-lactam agent.